{"id":989907,"date":"2026-08-05T04:31:16","date_gmt":"2026-08-05T08:31:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/"},"modified":"2026-08-05T04:31:16","modified_gmt":"2026-08-05T08:31:16","slug":"alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/","title":{"rendered":"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LOS ANGELES<\/span>, Aug. 4, 2026<\/span> \/PRNewswire\/ — Schall, Brown & Schwartz<\/a>\u00a0LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY<\/a>) for violations\u00a0of the securities laws.<\/p>\n

\n INVESTIGATION DETAILS: <\/b>The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Alnylam announced its Q2 2026 financial results on July 30, 2026. The Company revealed it had “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy.” Based on this news, shares of Alnylam fell by almost 28.4% on the same day.<\/p>\n

If you are a shareholder who suffered a loss, click here to participate<\/a>.<\/p>\n

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at\u00a0www.schallfirm.com<\/a>, or by email at\u00a0david@schallfirm.com<\/a><\/p>\n

\n WHY SBS?<\/b>\u00a0Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.<\/p>\n

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\n CONTACT:<\/b>\n <\/p>\n

Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com<\/a>
Office: 310-301-3335
info@schallfirm.com<\/a><\/p>\n

\n \"Cision\" View original content:https:\/\/www.prnewswire.com\/news-releases\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-302843239.html<\/a><\/p>\n

SOURCE Schall, Brown & Schwartz LLP<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire LOS ANGELES, Aug. 4, 2026 \/PRNewswire\/ — Schall, Brown & Schwartz\u00a0LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY) for violations\u00a0of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Alnylam announced its Q2 2026 financial results on July 30, 2026. The Company revealed it had “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up … <\/p>\n

Continue reading “ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-989907","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LOS ANGELES, Aug. 4, 2026 \/PRNewswire\/ — Schall, Brown & Schwartz\u00a0LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY) for violations\u00a0of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Alnylam announced its Q2 2026 financial results on July 30, 2026. The Company revealed it had “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up … Continue reading "ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T08:31:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA19635&sd=2026-08-05\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law\",\"datePublished\":\"2026-08-05T08:31:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/\"},\"wordCount\":329,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=LA19635&sd=2026-08-05\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/\",\"name\":\"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=LA19635&sd=2026-08-05\",\"datePublished\":\"2026-08-05T08:31:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=LA19635&sd=2026-08-05\",\"contentUrl\":\"https:\\\/\\\/edge.prnewswire.com\\\/c\\\/img\\\/favicon.png?sn=LA19635&sd=2026-08-05\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/","og_locale":"en_US","og_type":"article","og_title":"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Market Newsdesk","og_description":"PR Newswire LOS ANGELES, Aug. 4, 2026 \/PRNewswire\/ — Schall, Brown & Schwartz\u00a0LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (“Alnylam” or “the Company”) (NASDAQ: ALNY) for violations\u00a0of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and\/or misleading statements and\/or failed to disclose information pertinent to investors. Alnylam announced its Q2 2026 financial results on July 30, 2026. The Company revealed it had “lowered our TTR product sales guidance for full-year 2026 to reflect learnings from the initial phase of our launch in the evolving ATTR-CM market, in particular the normalization of growth in second line volume after satisfying pent-up … Continue reading \"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-05T08:31:16+00:00","og_image":[{"url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA19635&sd=2026-08-05","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law","datePublished":"2026-08-05T08:31:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/"},"wordCount":329,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA19635&sd=2026-08-05","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/","name":"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/#primaryimage"},"thumbnailUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA19635&sd=2026-08-05","datePublished":"2026-08-05T08:31:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/#primaryimage","url":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA19635&sd=2026-08-05","contentUrl":"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA19635&sd=2026-08-05"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alny-investors-have-opportunity-to-join-alnylam-pharmaceuticals-inc-fraud-investigation-with-sbs-law-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/989907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=989907"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/989907\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=989907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=989907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=989907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}